anti-psma car nk cells
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2018 (NCT03692663)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-psma car nk cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07298239 | Early Phase 1 (Phase 1) | Dec 18, 2025 | Chinese Academy of Medical Sciences |
| NCT07156045 | Early Phase 1 (Phase 1) | Aug 31, 2025 | Chinese Academy of Medical Sciences |
| NCT03692663 | Early Phase 1 (Phase 1) | Dec 31, 2018 | Allife Medical Science and Technology Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2025 |
| Allife Medical Science and Technology Co., Ltd. | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1